\-\ Texto\\:\\ \ \(0\)\
\-\ physical\\ exam\\ was\\ positive\\ for\\ pale\\ conjunctiva\\ and\\ skin\\,\\ bilateral\\ palpable\\ cervical\\ and\\ supraclavicular\\ lymph\\ nodes\\,\\ use\\ of\\ subcostal\\ muscles\\,\\ hepatomegaly\\,\\ and\\ decreased\\ bowel\\ sounds\\.\ \(0\)\
\-\ labs\\ included\\:\ \(0\)\
\-\ cbc\\:\\ wbc\\ 21\\.2\\,\\ hgb\\ 7\\.7\\,\\ hct\\ 23\\.7\\,\\ plt\\ 401\\.\\ bands\\ 2\\,\\ s\\ 91\\,\\ l\\ 5\\,\\ m\\ 2\\.\ \(0\)\
\-\ retics\\ 6\\.8\ \(0\)\
\-\ cmp\\:\\ na\\ 136\\,\\ k\\ 3\\.4\\,\\ cl\\ 100\\,\\ co2\\ 25\\,\\ bun\\ 9\\,\\ cr\\ 0\\.6\\,\\ glu\\ 99\\,\\ ca\\ 9\\.4\ \(0\)\
\-\ coagulation\\ studies\\:\\ pt\\ 17\\.4\\,\\ ptt\\ 169\\.2\\,\\ inr\\ 1\\.46\ \(0\)\
\-\ albumin\\ 2\\.7\ \(0\)\
\-\ total\\ protein\\ 7\\.7\ \(0\)\
\-\ total\\ bilirubin\\ 2\\.7\ \(0\)\
\-\ direct\\ bilirubin\\ 1\\.1\ \(0\)\
\-\ ast\\ 48\\,\\ alt\\ 33\ \(0\)\
\-\ alk\\ phos\\ 360\ \(0\)\
\-\ ldh\\ 233\ \(0\)\
\-\ uric\\ acid\\ 3\\.0\ \(0\)\
\-\ mycoplasma\\ pcr\\ negative\ \(0\)\
\-\ as\\ the\\ patient\\ was\\ experiencing\\ cough\\ and\\ dyspnea\\,\\ the\\ pleural\\ effusion\\ was\\ drained\\ multiple\\ times\\ using\\ fluoroscopy\\ before\\ he\\ could\\ be\\ sent\\ safely\\ for\\ biopsy\\.\\ imaging\\ directly\\ after\\ the\\ first\\ attempt\\ at\\ draining\\ the\\ pleural\\ effusion\\ is\\ shown\\,\\ with\\ little\\ improvement\\ despite\\ taking\\ off\\ about\\ 3l\\ of\\ fluid\\.\\ multiple\\ attempts\\ were\\ needed\\ to\\ fully\\ drain\\ the\\ effusion\\.\ \(0\)\
\-\ following\\ stabilization\\,\\ biopsy\\ and\\ histological\\ diagnosis\\,\\ he\\ was\\ placed\\ on\\ cog\\ protocol\\ ahod0831\\ for\\ high\\-risk\\ hodgkin\\"s\\ lymphoma\\.\\ he\\ received\\ induction\\ and\\ consolidation\\ chemotherapy\\ consisting\\ of\\ doxorubicin\\,\\ bleomycin\\,\\ vincristine\\,\\ etoposide\\,\\ cyclophosphamide\\ and\\ prednisone\\.\\ he\\ then\\ received\\ 14\\ sessions\\ of\\ focused\\ mediastinal\\ radiation\\.\ \(0\)\
\-\ he\\ has\\ since\\ been\\ followed\\ up\\ every\\ month\\ with\\ ct\\ scans\\ every\\ 3\\ months\\ which\\ have\\ shown\\ improving\\ residual\\ adenopathy\\.\\ it\\ is\\ now\\ about\\ one\\ year\\ and\\ two\\ months\\ post\\-diagnosis\\ and\\ he\\ has\\ had\\ no\\ recurrence\\ of\\ disease\\.\ \(0\)\
\-\ cxr\\:\\ the\\ left\\ hemithorax\\ is\\ almost\\ completely\\ opacified\\ and\\ shows\\ a\\ small\\ amount\\ of\\ aerated\\ lung\\ at\\ the\\ left\\ hilum\\.\\ there\\ is\\ also\\ evidence\\ of\\ lymphadenopathy\\.\ \(0\)\
\-\ ct\\:\\ massive\\ adenopathy\\ of\\ anterior\\ and\\ posterior\\ mediastinal\\ lymph\\ nodes\\ extending\\ anterior\\ to\\ the\\ heart\\.\\ retrosternal\\ lymph\\ node\\ mass\\ measuring\\ 5\\.8cm\\ at\\ maximal\\ diameter\\.\\ bilateral\\ enlarged\\ cervical\\ lymph\\ nodes\\ measuring\\ 4cm\\ at\\ maximal\\ diameter\\ and\\ one\\ enlarged\\ axillary\\ lymph\\ node\\.\\ pleural\\ effusion\\ with\\ associated\\ collapsed\\ left\\ lung\\.\\ small\\ pericardial\\ effusion\\.\\ splenomegaly\\.\ \(0\)\
\-\ cxr\\ after\\ drainage\\ of\\ pleural\\ effusion\\:\\ little\\ improvement\\ in\\ pleural\\ effusion\\.\ \(0\)\
\-\ stage\\ iv\\ hodgkins\\ lymphoma\\,\\ pleural\\ effusion\ \(0\)\
\-\ \\¬\\ù\\ lymphoma\ \(0\)\
\-\ \\¬\\ù\\ germ\\ cell\\ tumor\ \(0\)\
\-\ \\¬\\ù\\ sarcoid\ \(0\)\
\-\ \\¬\\ù\\ sarcoma\\ including\\ rhabdomyosarcoma\ \(0\)\
\-\ \\¬\\ù\\ histoplasmosis\ \(0\)\
\-\ \\¬\\ù\\ mononucleosis\ \(0\)\
\-\ \\¬\\ù\\ mycobacterial\\ infection\ \(0\)\
\-\ \\¬\\ù\\ thyroid\\ tumor\ \(0\)\
\-\ \\¬\\ù\\ langerhans\\ cell\\ histiocytosis\ \(0\)\
\-\ \\¬\\ù\\ thymoma\ \(0\)\
\-\ the\\ patient\\ presented\\ with\\ worsening\\ dry\\ cough\\ x\\ 1\\ month\\ with\\ associated\\ pallor\\ and\\ dyspnea\\.\\ he\\ had\\ also\\ had\\ an\\ unintentional\\ weight\\ loss\\ of\\ 15kg\\ and\\ had\\ been\\ sleeping\\ with\\ his\\ shirt\\ off\\ due\\ to\\ night\\ sweats\\.\\ one\\ day\\ prior\\ to\\ presentation\\,\\ the\\ patient\\"s\\ father\\ noted\\ enlarged\\ supraclavicular\\ lymph\\ nodes\\.\ \(0\)\
\-\ with\\ the\\ history\\ of\\ rapidly\\-growing\\ lymph\\ nodes\\ and\\ weight\\ loss\\,\\ our\\ patient\\ was\\ suspicious\\ for\\ malignancy\\ as\\ the\\ cause\\ of\\ the\\ opacity\\ on\\ the\\ initial\\ chest\\ xr\\.\\ differential\\ included\\ mass\\,\\ pleural\\ effusion\\ or\\ hemothorax\\.\\ further\\ evaluation\\ of\\ the\\ pleural\\ effusion\\ was\\ done\\ by\\ chest\\ ct\\ with\\ contrast\\.\\ this\\ was\\ chosen\\ because\\ ct\\ allows\\ for\\ differentiation\\ of\\ various\\ soft\\ tissues\\ and\\ liquid\\ densities\\.\\ the\\ entire\\ area\\ of\\ the\\ left\\ hemithorax\\ was\\ obscured\\ on\\ plain\\ film\\ and\\ therefore\\ ct\\ allowed\\ the\\ radiologist\\ to\\ differentiate\\ the\\ mediastinal\\ lymphadenopathy\\,\\ pleural\\ effusion\\ and\\ pericardial\\ effusion\\ that\\ were\\ found\\.\ \(0\)\
\-\ there\\ was\\ some\\ suspicion\\ for\\ a\\ bloody\\ pleural\\ effusion\\ from\\ lung\\ infiltration\\ of\\ the\\ patient\\‚\\Ä\\ôs\\ disease\\,\\ which\\ was\\ suspected\\ to\\ be\\ hodgkin\\‚\\Ä\\ôs\\ lymphoma\\ due\\ to\\ the\\ patient\\‚\\Ä\\ôs\\ age\\ and\\ the\\ massive\\ mediastinal\\ lymphadenopathy\\.\\ however\\,\\ bloody\\ effusion\\ from\\ direct\\ lung\\ involvement\\ is\\ more\\ likely\\ in\\ non\\-hodgkin\\"s\\ lymphoma\\ \\(light\\)\\.\\ indeed\\,\\ the\\ cytology\\ did\\ not\\ reveal\\ a\\ bloody\\ effusion\\.\\ eventually\\ the\\ patient\\ was\\ diagnosed\\ with\\ hodgkin\\‚\\Ä\\ôs\\ lymphoma\\ on\\ cervical\\ lymph\\ node\\ biopsy\\.\ \(0\)\
\-\ although\\ patients\\ with\\ hodgkin\\‚\\Ä\\ôs\\ lymphoma\\ often\\ present\\ with\\ a\\ mediastinal\\ mass\\,\\ a\\ pleural\\ effusion\\ is\\ not\\ typical\\.\\ one\\ review\\ showed\\ that\\ in\\ studies\\ of\\ malignant\\ pleural\\ effusions\\ in\\ adults\\,\\ up\\ to\\ 15\\%\\ have\\ been\\ associated\\ with\\ lymphomas\\ \\(das\\)\\.\\ in\\ children\\,\\ lymphoma\\ has\\ been\\ proven\\ to\\ be\\ the\\ most\\ common\\ cause\\ of\\ malignant\\ pleural\\ effusions\\ in\\ multiple\\ studies\\ \\(das\\,\\ cleveland\\)\\.\\ however\\,\\ pleural\\ effusion\\ is\\ more\\ common\\ in\\ non\\-hodgkin\\‚\\Ä\\ôs\\ lymphoma\\ and\\ is\\ rarely\\ present\\ in\\ hodgkin\\‚\\Ä\\ôs\\ lymphoma\\ at\\ diagnosis\\ \\(sahn\\)\\.\\ when\\ large\\ pleural\\ effusions\\ occur\\ with\\ lymphoma\\,\\ such\\ as\\ our\\ patient\\‚\\Ä\\ôs\\ effusion\\,\\ are\\ also\\ more\\ common\\ in\\ non\\-hodgkin\\‚\\Ä\\ôs\\ lymphoma\\ \\(cleveland\\)\\.\\ malignant\\ pleural\\ effusions\\ of\\ any\\ etiology\\ have\\ been\\ found\\ to\\ be\\ more\\ common\\ in\\ patients\\ over\\ 40\\ years\\ \\(das\\)\\.\ \(0\)\
\-\ pleural\\ effusions\\ that\\ do\\ occur\\ in\\ hodgkin\\‚\\Ä\\ôs\\ lymphoma\\ are\\ typically\\ caused\\ by\\ obstruction\\ of\\ lymphatic\\ vessels\\ from\\ mediastinal\\ lymph\\ node\\ involvement\\ \\(light\\)\\,\\ and\\ are\\ more\\ likely\\ to\\ happen\\ later\\ in\\ the\\ disease\\ course\\ rather\\ than\\ at\\ presentation\\ \\(cleveland\\)\\.\\ one\\ review\\ found\\ that\\ there\\ is\\ a\\ 30\\%\\ chance\\ of\\ pleural\\ effusion\\ with\\ progression\\ of\\ the\\ disease\\ and\\ 30\\-60\\%\\ incidence\\ of\\ pleural\\ effusion\\ at\\ autopsy\\ \\(sahn\\)\\.\\ a\\ study\\ of\\ autopsies\\ performed\\ on\\ 141\\ patients\\ with\\ hodgkin\\‚\\Ä\\ôs\\ lymphoma\\ ages\\ 15\\-78\\ found\\ a\\ 60\\%\\ incidence\\ of\\ pleural\\ effusions\\,\\ of\\ which\\ 74\\%\\ were\\ bilateral\\ \\(wong\\)\\.\\ \ \(0\)\
\-\ furthermore\\,\\ a\\ recent\\ review\\ reveals\\ that\\ most\\ recent\\ studies\\ on\\ malignant\\ effusions\\ associated\\ with\\ lymphoma\\ have\\ focused\\ on\\ non\\-hodgkin\\‚\\Ä\\ôs\\ lymphoma\\ \\(das\\)\\.\\ one\\ study\\ found\\ that\\ the\\ presence\\ or\\ absence\\ of\\ a\\ pleural\\ effusion\\ was\\ not\\ predictive\\ for\\ a\\ diagnosis\\ of\\ hodgkin\\‚\\Ä\\ôs\\ lymphoma\\ for\\ primary\\ mediastinal\\ lymphoma\\ \\(tateishi\\)\\.\\ \\ however\\,\\ one\\ french\\ study\\ did\\ reveal\\ 23\\.5\\%\\ of\\ hodgkin\\‚\\Ä\\ôs\\ lymphoma\\ cases\\ had\\ a\\ pleural\\ effusion\\ on\\ presentation\\;\\ methodology\\ and\\ demographic\\ information\\ were\\ not\\ available\\ for\\ this\\ study\\ to\\ evaluate\\ its\\ relevance\\ \\(essadki\\)\\.\\ a\\ pubmed\\ search\\ using\\ various\\ combinations\\ of\\ the\\ terms\\ \\‚\\Ä\\úhodgkin\\‚\\Ä\\ôs\\‚\\Ä\\ù\\ or\\ \\‚\\Ä\\úhodgkin\\‚\\Ä\\ôs\\ lymphoma\\‚\\Ä\\ù\\ and\\ \\‚\\Ä\\úpleural\\ effusion\\‚\\Ä\\ù\\ did\\ not\\ reveal\\ any\\ similar\\ studies\\.\\ \ \(0\)\
\-\ pericardial\\ effusions\\,\\ also\\ noted\\ in\\ our\\ patient\\,\\ have\\ been\\ found\\ to\\ be\\ most\\ commonly\\ caused\\ by\\ lymphomas\\ if\\ malignant\\,\\ but\\ are\\ uncommon\\ in\\ both\\ hodgkin\\‚\\Ä\\ôs\\ and\\ non\\-hodgkin\\‚\\Ä\\ôs\\ lymphoma\\ overall\\ \\(das\\)\\.\\ one\\ study\\ revealed\\ pericardial\\ effusions\\ in\\ only\\ 4\\%\\ of\\ hodgkin\\‚\\Ä\\ôs\\ lymphoma\\ patients\\ \\(essadki\\)\\.\\ splenomegaly\\ is\\ a\\ known\\,\\ but\\ relatively\\ uncommon\\ finding\\ in\\ hodgkin\\"s\\ lymphoma\\ \\(mcclain\\)\\.\ \(0\)\
\-\ the\\ combination\\ of\\ a\\ large\\ pleural\\ effusion\\,\\ pericardial\\ effusion\\ and\\ splenomegaly\\ make\\ this\\ an\\ unusual\\ presentation\\ of\\ hodgkin\\‚\\Ä\\ôs\\ lymphoma\\.\\ the\\ lack\\ of\\ blood\\ in\\ the\\ pleural\\ effusion\\,\\ however\\,\\ was\\ a\\ typical\\ feature\\ of\\ hodgkin\\‚\\Ä\\ôs\\ pleural\\ effusions\\.\ \(0\)\
\-\ Keywords\\ by\\ value\\:\\ \ \(0\)\
\-\ hodgkin\\:\\ 0\\.417503514425654\ \(0\)\
\-\ pleural\\:\\ 0\\.3809567555536666\ \(0\)\
\-\ effusion\\:\\ 0\\.3757874798671082\ \(0\)\
\-\ lymphoma\\:\\ 0\\.2782049472695431\ \(0\)\
\-\ effusions\\:\\ 0\\.18214820019797803\ \(0\)\
\-\ das\\:\\ 0\\.14871652667567806\ \(0\)\
\-\ lymph\\:\\ 0\\.13621688462736584\ \(0\)\
\-\ of\\:\\ 0\\.1333139918875601\ \(0\)\
\-\ the\\:\\ 0\\.12427919644439288\ \(0\)\
\-\ mediastinal\\:\\ 0\\.11001666481760501\ \(0\)\
\-\ and\\:\\ 0\\.10457062715991311\ \(0\)\
\-\ pericardial\\:\\ 0\\.09522370897400562\ \(0\)\
\-\ one\\:\\ 0\\.08915131887570371\ \(0\)\
\-\ was\\:\\ 0\\.08818305856626152\ \(0\)\
\-\ nodes\\:\\ 0\\.08267224921823715\ \(0\)\
\-\ in\\:\\ 0\\.08231317028090121\ \(0\)\
\-\ cleveland\\:\\ 0\\.08213469084152297\ \(0\)\
\-\ he\\:\\ 0\\.08068006621276207\ \(0\)\
\-\ found\\:\\ 0\\.07556362999156571\ \(0\)\
\-\ studies\\:\\ 0\\.07138851976366697\ \(0\)\
\-\ malignant\\:\\ 0\\.06937229993654455\ \(0\)\
\-\ been\\:\\ 0\\.06803883351354895\ \(0\)\
\-\ splenomegaly\\:\\ 0\\.06794424051375522\ \(0\)\
\-\ node\\:\\ 0\\.0669179161666728\ \(0\)\
\-\ bloody\\:\\ 0\\.0653244434960583\ \(0\)\
\-\ study\\:\\ 0\\.06490461884345923\ \(0\)\
\-\ to\\:\\ 0\\.06325671492879484\ \(0\)\
\-\ sahn\\:\\ 0\\.06225357110696801\ \(0\)\
\-\ essadki\\:\\ 0\\.06225357110696801\ \(0\)\
\-\ with\\:\\ 0\\.060979952898718146\ \(0\)\
\-\ patient\\:\\ 0\\.05697524897884428\ \(0\)\
\-\ presentation\\:\\ 0\\.053594103265142336\ \(0\)\
\-\ more\\:\\ 0\\.0534384233686737\ \(0\)\
\-\ is\\:\\ 0\\.05330282234897722\ \(0\)\
\-\ for\\:\\ 0\\.05309383974718489\ \(0\)\
\-\ our\\:\\ 0\\.051728797180887756\ \(0\)\
\-\ at\\:\\ 0\\.0514619533510398\ \(0\)\
\-\ that\\:\\ 0\\.05067924506566498\ \(0\)\
\-\ lymphomas\\:\\ 0\\.050620090367363355\ \(0\)\
\-\ reveal\\:\\ 0\\.04911747037150032\ \(0\)\
\-\ have\\:\\ 0\\.04861607250508739\ \(0\)\
\-\ had\\:\\ 0\\.04848779813940377\ \(0\)\
\-\ review\\:\\ 0\\.048086537325696635\ \(0\)\
\-\ lung\\:\\ 0\\.047360114674946184\ \(0\)\
\-\ lymphadenopathy\\:\\ 0\\.04720608836792564\ \(0\)\
\-\ on\\:\\ 0\\.04702711089874636\ \(0\)\
\-\ focused\\:\\ 0\\.046207400478980316\ \(0\)\
\-\ however\\:\\ 0\\.0460810751048322\ \(0\)\
\-\ maximal\\:\\ 0\\.04449238957836582\ \(0\)\
\-\ common\\:\\ 0\\.044152719651475186\ \(0\)\
\-\ patients\\:\\ 0\\.04379771231880579\ \(0\)\
\-\ supraclavicular\\:\\ 0\\.0425291999058067\ \(0\)\
\-\ did\\:\\ 0\\.041887555814914226\ \(0\)\
\-\ cervical\\:\\ 0\\.041820869936340925\ \(0\)\
\-\ bilirubin\\:\\ 0\\.04181020245674035\ \(0\)\
\-\ associated\\:\\ 0\\.04103543918491651\ \(0\)\
\-\ biopsy\\:\\ 0\\.04093020006293499\ \(0\)\
\-\ diagnosis\\:\\ 0\\.04035949578409099\ \(0\)\
\-\ were\\:\\ 0\\.040132018381470055\ \(0\)\
\-\ massive\\:\\ 0\\.040019785660652084\ \(0\)\
\-\ enlarged\\:\\ 0\\.03980610806268558\ \(0\)\
\-\ hemithorax\\:\\ 0\\.03963702193564752\ \(0\)\
\-\ be\\:\\ 0\\.03947834154443779\ \(0\)\
\-\ various\\:\\ 0\\.03893044335098271\ \(0\)\
\-\ not\\:\\ 0\\.03841914238150199\ \(0\)\
\-\ little\\:\\ 0\\.038290208769223975\ \(0\)\
\-\ every\\:\\ 0\\.03770492190276267\ \(0\)\
\-\ ct\\:\\ 0\\.03705017615421233\ \(0\)\
\-\ also\\:\\ 0\\.036620774886320366\ \(0\)\
\-\ uncommon\\:\\ 0\\.03522433204726448\ \(0\)\
\-\ direct\\:\\ 0\\.034313091910787644\ \(0\)\
\-\ dyspnea\\:\\ 0\\.03425645951850278\ \(0\)\
\-\ improvement\\:\\ 0\\.0339801398237717\ \(0\)\
\-\ received\\:\\ 0\\.03387267045143253\ \(0\)\
\-\ light\\:\\ 0\\.03371457463705849\ \(0\)\
\-\ included\\:\\ 0\\.033662679602898815\ \(0\)\
\-\ incidence\\:\\ 0\\.03350932114664998\ \(0\)\
\-\ adenopathy\\:\\ 0\\.03274498024766688\ \(0\)\
\-\ disease\\:\\ 0\\.032680775813287564\ \(0\)\
\-\ off\\:\\ 0\\.03252267511469938\ \(0\)\
\-\ using\\:\\ 0\\.03201695015121257\ \(0\)\
\-\ total\\:\\ 0\\.031896165332492135\ \(0\)\
\-\ bilateral\\:\\ 0\\.031381624575653834\ \(0\)\
\-\ diameter\\:\\ 0\\.031285777562243565\ \(0\)\
\-\ caused\\:\\ 0\\.03121317938707491\ \(0\)\
\-\ cxr\\:\\ 0\\.03114134541741171\ \(0\)\
\-\ retics\\:\\ 0\\.031126785553484006\ \(0\)\
\-\ ahod0831\\:\\ 0\\.031126785553484006\ \(0\)\
\-\ tateishi\\:\\ 0\\.031126785553484006\ \(0\)\
\-\ mcclain\\:\\ 0\\.031126785553484006\ \(0\)\
\-\ most\\:\\ 0\\.030388586418218327\ \(0\)\
\-\ shown\\:\\ 0\\.030176721717135688\ \(0\)\
\-\ measuring\\:\\ 0\\.030114964154421945\ \(0\)\
\-\ typical\\:\\ 0\\.030084293702321442\ \(0\)\
\-\ 15kg\\:\\ 0\\.029743305335135615\ \(0\)\
\-\ are\\:\\ 0\\.02954244309596029\ \(0\)\
\-\ about\\:\\ 0\\.029142520342176615\ \(0\)\
\-\ 60\\:\\ 0\\.029115915380192675\ \(0\)\
\-\ cough\\:\\ 0\\.029063014618339652\ \(0\)\
\-\ 3l\\:\\ 0\\.02876171049885605\ \(0\)\
\-\ cog\\:\\ 0\\.02876171049885605\ \(0\)\
\-\ autopsies\\:\\ 0\\.02876171049885605\ \(0\)\
\-\ methodology\\:\\ 0\\.02876171049885605\ \(0\)\
\-\ relevance\\:\\ 0\\.02876171049885605\ \(0\)\
\-\ occur\\:\\ 0\\.028629183371090414\ \(0\)\
\-\ multiple\\:\\ 0\\.028560442243756527\ \(0\)\
\-\ involvement\\:\\ 0\\.028174868121855632\ \(0\)\
\-\ shirt\\:\\ 0\\.028000326392254048\ \(0\)\
\-\ combinations\\:\\ 0\\.028000326392254048\ \(0\)\
\-\ 360\\:\\ 0\\.027378230280507655\ \(0\)\
\-\ bleomycin\\:\\ 0\\.027378230280507655\ \(0\)\
\-\ happen\\:\\ 0\\.027378230280507655\ \(0\)\
\-\ wong\\:\\ 0\\.027378230280507655\ \(0\)\
\-\ weight\\:\\ 0\\.02714609064235121\ \(0\)\
\-\ subcostal\\:\\ 0\\.026852255512466512\ \(0\)\
\-\ 233\\:\\ 0\\.026852255512466512\ \(0\)\
\-\ sessions\\:\\ 0\\.026852255512466512\ \(0\)\
\-\ has\\:\\ 0\\.026671431932133255\ \(0\)\
\-\ left\\:\\ 0\\.026558048784473366\ \(0\)\
\-\ 30\\:\\ 0\\.026555627452987653\ \(0\)\
\-\ which\\:\\ 0\\.02655109260455578\ \(0\)\
\-\ cause\\:\\ 0\\.02651923182482152\ \(0\)\
\-\ french\\:\\ 0\\.026396635444228093\ \(0\)\
\-\ recent\\:\\ 0\\.02635781174435661\ \(0\)\
\-\ 15\\:\\ 0\\.026304842546161143\ \(0\)\
\-\ safely\\:\\ 0\\.02599475006215926\ \(0\)\
\-\ induction\\:\\ 0\\.02599475006215926\ \(0\)\
\-\ etoposide\\:\\ 0\\.02599475006215926\ \(0\)\
\-\ demographic\\:\\ 0\\.02599475006215926\ \(0\)\
\-\ glu\\:\\ 0\\.025310045183681677\ \(0\)\
\-\ mononucleosis\\:\\ 0\\.025310045183681677\ \(0\)\
\-\ any\\:\\ 0\\.02515807677324603\ \(0\)\
\-\ conjunctiva\\:\\ 0\\.0250131552258797\ \(0\)\
\-\ mycoplasma\\:\\ 0\\.0250131552258797\ \(0\)\
\-\ pallor\\:\\ 0\\.0250131552258797\ \(0\)\
\-\ unintentional\\:\\ 0\\.0250131552258797\ \(0\)\
\-\ indeed\\:\\ 0\\.0250131552258797\ \(0\)\
\-\ by\\:\\ 0\\.024796320876024614\ \(0\)\
\-\ uric\\:\\ 0\\.024740042939581958\ \(0\)\
\-\ pcr\\:\\ 0\\.024740042939581958\ \(0\)\
\-\ xr\\:\\ 0\\.024740042939581958\ \(0\)\
\-\ predictive\\:\\ 0\\.024740042939581958\ \(0\)\
\-\ retrosternal\\:\\ 0\\.024487180457838556\ \(0\)\
\-\ chosen\\:\\ 0\\.024487180457838556\ \(0\)\
\-\ 141\\:\\ 0\\.024487180457838556\ \(0\)\
\-\ hepatomegaly\\:\\ 0\\.024251771119277694\ \(0\)\
\-\ doxorubicin\\:\\ 0\\.024251771119277694\ \(0\)\
\-\ cyclophosphamide\\:\\ 0\\.024251771119277694\ \(0\)\
\-\ aerated\\:\\ 0\\.024251771119277694\ \(0\)\
\-\ hodgkins\\:\\ 0\\.023824704205552074\ \(0\)\
\-\ autopsy\\:\\ 0\\.023824704205552074\ \(0\)\
\-\ loss\\:\\ 0\\.023716068841122203\ \(0\)\
\-\ month\\:\\ 0\\.023680057337473092\ \(0\)\
\-\ as\\:\\ 0\\.023457846520780423\ \(0\)\
\-\ 136\\:\\ 0\\.023445193212198772\ \(0\)\
\-\ mycobacterial\\:\\ 0\\.023445193212198772\ \(0\)\
\-\ liquid\\:\\ 0\\.023445193212198772\ \(0\)\
\-\ opacified\\:\\ 0\\.023270176282998132\ \(0\)\
\-\ obscured\\:\\ 0\\.023270176282998132\ \(0\)\
\-\ likely\\:\\ 0\\.02326212078842792\ \(0\)\
\-\ there\\:\\ 0\\.02323370614099657\ \(0\)\
\-\ from\\:\\ 0\\.023190537932968575\ \(0\)\
\-\ attempts\\:\\ 0\\.023103700239490158\ \(0\)\
\-\ allowed\\:\\ 0\\.023103700239490158\ \(0\)\
\-\ vincristine\\:\\ 0\\.02294497012905372\ \(0\)\
\-\ sleeping\\:\\ 0\\.02294497012905372\ \(0\)\
\-\ cytology\\:\\ 0\\.02294497012905372\ \(0\)\
\-\ improving\\:\\ 0\\.02279329706777748\ \(0\)\
\-\ collapsed\\:\\ 0\\.02279329706777748\ \(0\)\
\-\ months\\:\\ 0\\.022658963155111744\ \(0\)\
\-\ coagulation\\:\\ 0\\.02264808017125174\ \(0\)\
\-\ pale\\:\\ 0\\.02250879217639613\ \(0\)\
\-\ due\\:\\ 0\\.0223762650486305\ \(0\)\
\-\ chance\\:\\ 0\\.022374967884954\ \(0\)\
\-\ mass\\:\\ 0\\.02230390735438306\ \(0\)\
\-\ cell\\:\\ 0\\.02226833209393285\ \(0\)\
\-\ ptt\\:\\ 0\\.02224619478918291\ \(0\)\
\-\ lymphatic\\:\\ 0\\.02224619478918291\ \(0\)\
\-\ feature\\:\\ 0\\.02224619478918291\ \(0\)\
\-\ drained\\:\\ 0\\.022122105403210596\ \(0\)\
\-\ stabilization\\:\\ 0\\.022122105403210596\ \(0\)\
\-\ pubmed\\:\\ 0\\.022122105403210596\ \(0\)\
\-\ terms\\:\\ 0\\.022122105403210596\ \(0\)\
\-\ albumin\\:\\ 0\\.022002370940679042\ \(0\)\
\-\ fluoroscopy\\:\\ 0\\.021886696064649738\ \(0\)\
\-\ anterior\\:\\ 0\\.021734849662420955\ \(0\)\
\-\ cmp\\:\\ 0\\.021666485334972178\ \(0\)\
\-\ co2\\:\\ 0\\.021666485334972178\ \(0\)\
\-\ consisting\\:\\ 0\\.021666485334972178\ \(0\)\
\-\ histoplasmosis\\:\\ 0\\.021666485334972178\ \(0\)\
\-\ hemothorax\\:\\ 0\\.021666485334972178\ \(0\)\
\-\ cl\\:\\ 0\\.021561489910705323\ \(0\)\
\-\ 91\\:\\ 0\\.021459629150924114\ \(0\)\
\-\ histological\\:\\ 0\\.021459629150924114\ \(0\)\
\-\ experiencing\\:\\ 0\\.02126459995290335\ \(0\)\
\-\ thymoma\\:\\ 0\\.02126459995290335\ \(0\)\
\-\ allows\\:\\ 0\\.02126459995290335\ \(0\)\
\-\ ldh\\:\\ 0\\.02117111240481528\ \(0\)\
\-\ furthermore\\:\\ 0\\.02117111240481528\ \(0\)\
\-\ fully\\:\\ 0\\.020991487666605604\ \(0\)\
\-\ plt\\:\\ 0\\.020905101228370176\ \(0\)\
\-\ hilum\\:\\ 0\\.020905101228370176\ \(0\)\
\-\ inr\\:\\ 0\\.020820848008117728\ \(0\)\
\-\ father\\:\\ 0\\.020738625184862202\ \(0\)\
\-\ bands\\:\\ 0\\.020658337196959142\ \(0\)\
\-\ noted\\:\\ 0\\.020639311479254293\ \(0\)\
\-\ chest\\:\\ 0\\.02054791505811896\ \(0\)\
\-\ prednisone\\:\\ 0\\.02050321584630134\ \(0\)\
\-\ 4cm\\:\\ 0\\.02050321584630134\ \(0\)\
\-\ dry\\:\\ 0\\.02050321584630134\ \(0\)\
\-\ differentiate\\:\\ 0\\.02050321584630134\ \(0\)\
\-\ langerhans\\:\\ 0\\.02042822201314952\ \(0\)\
\-\ tumor\\:\\ 0\\.020361348925123087\ \(0\)\
\-\ alk\\:\\ 0\\.020354841076294632\ \(0\)\
\-\ or\\:\\ 0\\.020313283990721492\ \(0\)\
\-\ search\\:\\ 0\\.020283005116623783\ \(0\)\
\-\ acid\\:\\ 0\\.02021265041682106\ \(0\)\
\-\ cr\\:\\ 0\\.020143717121768174\ \(0\)\
\-\ phos\\:\\ 0\\.020143717121768174\ \(0\)\
\-\ small\\:\\ 0\\.020080123289055424\ \(0\)\
\-\ attempt\\:\\ 0\\.02007614893257572\ \(0\)\
\-\ radiologist\\:\\ 0\\.02007614893257572\ \(0\)\
\-\ this\\:\\ 0\\.020064292796606865\ \(0\)\
\-\ present\\:\\ 0\\.019974972301010772\ \(0\)\
\-\ sweats\\:\\ 0\\.01988111973455495\ \(0\)\
\-\ ages\\:\\ 0\\.01988111973455495\ \(0\)\
\-\ rhabdomyosarcoma\\:\\ 0\\.01969663793922242\ \(0\)\
\-\ proven\\:\\ 0\\.019637295886051086\ \(0\)\
\-\ histiocytosis\\:\\ 0\\.019521621010021778\ \(0\)\
\-\ large\\:\\ 0\\.019504617395278357\ \(0\)\
\-\ densities\\:\\ 0\\.019465221675491355\ \(0\)\
\-\ drain\\:\\ 0\\.019409739444058143\ \(0\)\
\-\ eventually\\:\\ 0\\.019409739444058143\ \(0\)\
\-\ directly\\:\\ 0\\.019355144966513804\ \(0\)\
\-\ 74\\:\\ 0\\.019355144966513804\ \(0\)\
\-\ up\\:\\ 0\\.01925597485194443\ \(0\)\
\-\ but\\:\\ 0\\.019249717021056316\ \(0\)\
\-\ information\\:\\ 0\\.01924850872372404\ \(0\)\
\-\ infiltration\\:\\ 0\\.019196414856077367\ \(0\)\
\-\ axillary\\:\\ 0\\.019145104384611988\ \(0\)\
\-\ 99\\:\\ 0\\.019094554096296158\ \(0\)\
\-\ protocol\\:\\ 0\\.01899564624198064\ \(0\)\
\-\ hgb\\:\\ 0\\.01889952489827539\ \(0\)\
\-\ differentiation\\:\\ 0\\.01889952489827539\ \(0\)\
\-\ make\\:\\ 0\\.01889952489827539\ \(0\)\
\-\ after\\:\\ 0\\.018884375685653185\ \(0\)\
\-\ draining\\:\\ 0\\.018852460951381336\ \(0\)\
\-\ taking\\:\\ 0\\.018852460951381336\ \(0\)\
\-\ bun\\:\\ 0\\.018760236903419776\ \(0\)\
\-\ alt\\:\\ 0\\.01871504310294286\ \(0\)\
\-\ ast\\:\\ 0\\.018670440088036224\ \(0\)\
\-\ suspicion\\:\\ 0\\.018497639516206556\ \(0\)\
\-\ hct\\:\\ 0\\.018455772953489772\ \(0\)\
\-\ na\\:\\ 0\\.018455772953489772\ \(0\)\
\-\ sarcoid\\:\\ 0\\.01825381566770269\ \(0\)\
\-\ sent\\:\\ 0\\.018214820019797805\ \(0\)\
\-\ germ\\:\\ 0\\.018176265010113022\ \(0\)\
\-\ adults\\:\\ 0\\.018176265010113022\ \(0\)\
\-\ protein\\:\\ 0\\.018063146958521563\ \(0\)\
\-\ combination\\:\\ 0\\.018063146958521563\ \(0\)\
\-\ consolidation\\:\\ 0\\.017989766021666676\ \(0\)\
\-\ overall\\:\\ 0\\.01788257138233649\ \(0\)\
\-\ progression\\:\\ 0\\.017847575362193103\ \(0\)\
\-\ residual\\:\\ 0\\.017711073877947764\ \(0\)\
\-\ entire\\:\\ 0\\.017711073877947764\ \(0\)\
\-\ times\\:\\ 0\\.017516044679926995\ \(0\)\
\-\ almost\\:\\ 0\\.01748459669645809\ \(0\)\
\-\ night\\:\\ 0\\.01748459669645809\ \(0\)\
\-\ unusual\\:\\ 0\\.0174534359131958\ \(0\)\
\-\ completely\\:\\ 0\\.01739195529395468\ \(0\)\
\-\ suspicious\\:\\ 0\\.01739195529395468\ \(0\)\
\-\ rarely\\:\\ 0\\.017361625476005418\ \(0\)\
\-\ rather\\:\\ 0\\.017242932393629253\ \(0\)\
\-\ therefore\\:\\ 0\\.017156545955393822\ \(0\)\
\-\ 33\\:\\ 0\\.01712822975925139\ \(0\)\
\-\ despite\\:\\ 0\\.016936335225716265\ \(0\)\
\-\ scans\\:\\ 0\\.016936335225716265\ \(0\)\
\-\ opacity\\:\\ 0\\.016936335225716265\ \(0\)\
\-\ 48\\:\\ 0\\.016857287318529247\ \(0\)\
\-\ muscles\\:\\ 0\\.016679666740173165\ \(0\)\
\-\ lack\\:\\ 0\\.016655030661647204\ \(0\)\
\-\ ca\\:\\ 0\\.016606285803318282\ \(0\)\
\-\ sarcoma\\:\\ 0\\.016327593659599366\ \(0\)\
\-\ cbc\\:\\ 0\\.016239535041936867\ \(0\)\
\-\ do\\:\\ 0\\.016132564461578597\ \(0\)\
\-\ needed\\:\\ 0\\.01606995569484741\ \(0\)\
\-\ recurrence\\:\\ 0\\.01606995569484741\ \(0\)\
\-\ 100\\:\\ 0\\.015968094935066197\ \(0\)\
\-\ suspected\\:\\ 0\\.015948082666246068\ \(0\)\
\-\ children\\:\\ 0\\.015948082666246068\ \(0\)\
\-\ relatively\\:\\ 0\\.015849744965169846\ \(0\)\
\-\ before\\:\\ 0\\.015735362789308545\ \(0\)\
\-\ etiology\\:\\ 0\\.015679578188957363\ \(0\)\
\-\ drainage\\:\\ 0\\.0155885839417129\ \(0\)\
\-\ amount\\:\\ 0\\.015570672708705855\ \(0\)\
\-\ absence\\:\\ 0\\.015517496327708529\ \(0\)\
\-\ stage\\:\\ 0\\.015499953450747686\ \(0\)\
\-\ done\\:\\ 0\\.015482500307565143\ \(0\)\
\-\ tissues\\:\\ 0\\.015345998823319804\ \(0\)\
\-\ thyroid\\:\\ 0\\.015296186521824772\ \(0\)\
\-\ placed\\:\\ 0\\.015166802981101223\ \(0\)\
\-\ evaluate\\:\\ 0\\.015135209403040648\ \(0\)\
\-\ vessels\\:\\ 0\\.015103905678404984\ \(0\)\
\-\ sounds\\:\\ 0\\.015026880239326725\ \(0\)\
\-\ use\\:\\ 0\\.014892470132439316\ \(0\)\
\-\ an\\:\\ 0\\.01488575108521686\ \(0\)\
\-\ worsening\\:\\ 0\\.014863306860436715\ \(0\)\
\-\ similar\\:\\ 0\\.014834390737777984\ \(0\)\
\-\ reveals\\:\\ 0\\.01480571761061868\ \(0\)\
\-\ malignancy\\:\\ 0\\.014571260171088308\ \(0\)\
\-\ film\\:\\ 0\\.014544706869354832\ \(0\)\
\-\ 14\\:\\ 0\\.014531507309169826\ \(0\)\
\-\ skin\\:\\ 0\\.01447921384036175\ \(0\)\
\-\ its\\:\\ 0\\.014402246320060857\ \(0\)\
\-\ commonly\\:\\ 0\\.014402246320060857\ \(0\)\
\-\ course\\:\\ 0\\.01437697152262066\ \(0\)\
\-\ 40\\:\\ 0\\.014314591685545207\ \(0\)\
\-\ could\\:\\ 0\\.014157547802992177\ \(0\)\
\-\ since\\:\\ 0\\.014099020089216747\ \(0\)\
\-\ diagnosed\\:\\ 0\\.014099020089216747\ \(0\)\
\-\ pt\\:\\ 0\\.014007415069205482\ \(0\)\
\-\ presence\\:\\ 0\\.013984892993686944\ \(0\)\
\-\ including\\:\\ 0\\.013929229735537896\ \(0\)\
\-\ later\\:\\ 0\\.013929229735537896\ \(0\)\
\-\ iv\\:\\ 0\\.01390721622658374\ \(0\)\
\-\ chemotherapy\\:\\ 0\\.013820555516248756\ \(0\)\
\-\ 25\\:\\ 0\\.013788616917504066\ \(0\)\
\-\ then\\:\\ 0\\.013778036809638882\ \(0\)\
\-\ wbc\\:\\ 0\\.013756974507866122\ \(0\)\
\-\ palpable\\:\\ 0\\.013674001858862576\ \(0\)\
\-\ typically\\:\\ 0\\.013663770720604254\ \(0\)\
\-\ obstruction\\:\\ 0\\.013633260096568912\ \(0\)\
\-\ because\\:\\ 0\\.01360301988043824\ \(0\)\
\-\ heart\\:\\ 0\\.013533484506381473\ \(0\)\
\-\ labs\\:\\ 0\\.013484669910541888\ \(0\)\
\-\ now\\:\\ 0\\.013360926735523419\ \(0\)\
\-\ although\\:\\ 0\\.013250553272149038\ \(0\)\
\-\ available\\:\\ 0\\.013205597654077899\ \(0\)\
\-\ extending\\:\\ 0\\.013196677173042338\ \(0\)\
\-\ followed\\:\\ 0\\.013143638560245212\ \(0\)\
\-\ first\\:\\ 0\\.013134878396119732\ \(0\)\
\-\ cases\\:\\ 0\\.01309141179489642\ \(0\)\
\-\ initial\\:\\ 0\\.013057032843576968\ \(0\)\
\-\ showed\\:\\ 0\\.012964238737631853\ \(0\)\
\-\ radiation\\:\\ 0\\.012898302733140526\ \(0\)\
\-\ plain\\:\\ 0\\.012841635773836237\ \(0\)\
\-\ positive\\:\\ 0\\.012825616579845902\ \(0\)\
\-\ finding\\:\\ 0\\.01279380206448284\ \(0\)\
\-\ revealed\\:\\ 0\\.012762281451844772\ \(0\)\
\-\ often\\:\\ 0\\.012700100559219432\ \(0\)\
\-\ further\\:\\ 0\\.012677071796532767\ \(0\)\
\-\ differential\\:\\ 0\\.012646606575815466\ \(0\)\
\-\ area\\:\\ 0\\.012608903628078587\ \(0\)\
\-\ known\\:\\ 0\\.01260141277533855\ \(0\)\
\-\ such\\:\\ 0\\.012520080858391812\ \(0\)\
\-\ bowel\\:\\ 0\\.012490979768960516\ \(0\)\
\-\ day\\:\\ 0\\.012398079649995472\ \(0\)\
\-\ some\\:\\ 0\\.01224640658871923\ \(0\)\
\-\ age\\:\\ 0\\.012219539662089845\ \(0\)\
\-\ only\\:\\ 0\\.012159851573519133\ \(0\)\
\-\ decreased\\:\\ 0\\.012056250991118784\ \(0\)\
\-\ negative\\:\\ 0\\.012049879220728114\ \(0\)\
\-\ primary\\:\\ 0\\.01196811112953865\ \(0\)\
\-\ years\\:\\ 0\\.01193102291598101\ \(0\)\
\-\ evaluation\\:\\ 0\\.011870091260147502\ \(0\)\
\-\ his\\:\\ 0\\.011804299734391515\ \(0\)\
\-\ infection\\:\\ 0\\.011757235787497464\ \(0\)\
\-\ when\\:\\ 0\\.011757235787497464\ \(0\)\
\-\ following\\:\\ 0\\.011676404344619511\ \(0\)\
\-\ two\\:\\ 0\\.011558637974691777\ \(0\)\
\-\ performed\\:\\ 0\\.011514822514792132\ \(0\)\
\-\ shows\\:\\ 0\\.011423541862876108\ \(0\)\
\-\ presented\\:\\ 0\\.011350160926021223\ \(0\)\
\-\ if\\:\\ 0\\.011308926804234619\ \(0\)\
\-\ blood\\:\\ 0\\.011303807400344555\ \(0\)\
\-\ fluid\\:\\ 0\\.011237944825810283\ \(0\)\
\-\ evidence\\:\\ 0\\.011047657924664982\ \(0\)\
\-\ than\\:\\ 0\\.011033450761657626\ \(0\)\
\-\ prior\\:\\ 0\\.010890006528806348\ \(0\)\
\-\ both\\:\\ 0\\.010853947201892521\ \(0\)\
\-\ over\\:\\ 0\\.010822704898111954\ \(0\)\
\-\ physical\\:\\ 0\\.010553696138529666\ \(0\)\
\-\ soft\\:\\ 0\\.010362090320000086\ \(0\)\
\-\ imaging\\:\\ 0\\.01022886327729966\ \(0\)\
\-\ posterior\\:\\ 0\\.01006487689610765\ \(0\)\
\-\ it\\:\\ 0\\.009963225434412852\ \(0\)\
\-\ exam\\:\\ 0\\.009798065272931462\ \(0\)\
\-\ contrast\\:\\ 0\\.009457042381101547\ \(0\)\
\-\ history\\:\\ 0\\.007436282145285954\ \(0\)\
\-\ no\\:\\ 0\\.006329392474072505\ \(0\)\
\-\ year\\:\\ 0\\.005998346860304484\ \(0\)\
